However, one study in CRC found superior benefit from chemotherapy intensification in patients with medium/high TROP2 levels, and preclinical studies show the selective response of TROP2-expressing cells to SG.12-14 Furthermore, the COGNITION-GUIDE trial (NCT05332561) is currently enrolling patients with high-risk early breast cancer to test the efficacy of adjuvant targeted therapies including SG for TROP2-positive tumors. This evidence concerns the gene TACSTD2 and breast carcinoma.